Bruker AXS

November 15, 2005 16:15 ET

Bruker AXS Announces Closing of Acquisitions of Roentec AG and Princeton Gamma-Tech Microanalysis Business

BERLIN and ROCKY HILL, N.J.--(CCNMatthews - Nov 15, 2005) -

Simultaneous Acquisitions Strengthen Bruker AXS Presence in Nanotechnology and Advanced Materials Research Markets

Bruker AXS Inc. today announced the closing of two complementary acquisitions in the $150 million per annum X-ray microanalysis market. Applications of microanalysis include nanotechnology and advanced materials research, as well as materials analysis and quality control, with customers in many industries, academia and government research facilities.

On October 14th and 26th, 2005, Bruker AXS had announced agreements for the acquisition of Roentec AG and the microanalysis business of Princeton Gamma-Tech (PGT) Instruments, Inc., respectively. Following the completion of the two closings in the last two business days, Bruker AXS has now combined the two units into a newly created 'Bruker AXS Microanalysis' business, under the responsibility of Bruker AXS Executive Vice President Roger Durst, with operations in Berlin (Germany), Coventry (UK), as well as Madison, WI and the Princeton, NJ area in the United States.

Bruker AXS also has integrated the management teams of both microanalysis units, and announces the appointment of Mr. Thomas Schuelein, previously with Roentec, as Vice President for Microanalysis. Mr. Douglas Skinner, previously with PGT, has been appointed as Assistant Vice President for Microanalysis.

Frank Laukien, President and CEO of Bruker BioSciences, stated: "We are excited to welcome both of these outstanding teams to Bruker AXS. The strong synergies between Roentec and the PGT microanalysis business, in combination with our proprietary X-ray technologies and our global sales and support infrastructure, will make the new Bruker AXS Microanalysis business stronger than the sum of its parts. Moreover, our worldwide distribution capabilities can also enhance the revenue growth for the novel transportable microXRF and TXRF systems that have been pioneered by Roentec. Overall, we believe that this acquisition increases the accessible market for Bruker BioSciences, that it will further accelerate our growth and profitability, and that for our shareholders it will be accretive to cash EPS already in 2006."


Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit


Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.


Contact Information